September 22, 2025Canadian Hematology TodayOpen Access

Front-line Treatment for Chronic Lymphocytic Leukemia in 2025: Finite Duration Versus Continuous Treatment

View Full Paper

Ask AI

Bookmark

Patients with chronic lymphocytic leukemia now face a choice between fixed-duration or continuous treatment based on recent advancements.
This analysis highlights how targeted treatments like venetoclax and BTK inhibitors can improve management of CLL effectively.
The findings summarize evidence from recent studies, allowing clinicians to make informed decisions regarding treatment strategies.
Future treatment decisions will depend on individual patient factors and evolving therapeutic options in CLL management.

Discussion

No takes yet. Share an insight, caveat, or question.

This review compares fixed-duration and continuous treatment approaches for CLL, suggesting considerations for treatment selection.

Abeyakoon et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark